Texas attorney general sues Tylenol company over autism claims

Texas Attorney General Ken Paxton has filed a lawsuit against Johnson & Johnson and its subsidiary Kenvue, alleging the companies failed to warn consumers about a potential link between Tylenol use during pregnancy and autism, seeking potentially tens of billions of dollars in damages. This state action, utilizing consumer protection laws and targeting Kenvue as a liability shield, follows broader multi-district litigation and controversial guidance from federal officials, despite major medical associations and some scientific studies disputing a causal link. Kenvue stated it will vigorously defend itself, asserting the scientific and legal claims lack merit, highlighting significant legal and financial risk for the pharmaceutical giant amidst ongoing scientific debate.

Analysis

Texas Attorney General Ken Paxton has initiated a novel lawsuit against Johnson & Johnson (JNJ) and its spin-off Kenvue (KVUE), alleging failure to warn consumers about a potential link between prenatal Tylenol use and autism. This state-level action, distinct from ongoing personal injury multi-district litigation, leverages consumer protection laws and seeks "tens of billions of dollars" in damages, specifically targeting Kenvue as a potential liability shield. The lawsuit intensifies legal pressure on both entities, following recent controversial federal guidance from Trump and Kennedy Jr. discouraging acetaminophen use during pregnancy.

The scientific community remains divided on the alleged causal link, with some studies suggesting correlation while major medical associations and a large Swedish study repudiate such findings, indicating "no causal effect." Kenvue has publicly committed to "vigorously defend itself," asserting the claims lack both legal merit and scientific support. This stance is reinforced by a recent federal judge's decision to exclude expert witnesses in related multi-district litigation due to insufficient scientific evidence, though this decision is under appeal.

The lawsuit introduces significant financial risk for JNJ and KVUE, given the substantial damages sought and Texas's history of successful litigation against J&J, including a $290 million opioid settlement. The legal challenge also carries reputational implications, particularly for Kenvue, which was spun off in part to manage consumer health product liabilities. The political context, with AG Paxton running for re-election, adds another layer of complexity to the proceedings.

Key Decisions for Investors

• Investors should closely monitor the legal proceedings, including the appeal of the expert witness exclusion, as these outcomes will significantly influence potential liabilities for JNJ and KVUE.
• Assess potential financial impact by modeling the "tens of billions of dollars" in damages sought, considering Texas's track record in litigation against J&J, and its effect on JNJ's balance sheet and KVUE's valuation.
• Evaluate Kenvue's specific risk profile, as the lawsuit explicitly targets it as a potential liability shield, increasing scrutiny on its operational independence and financial resilience against such claims.
• Consider the broader reputational and regulatory risks that could arise from this ongoing controversy, potentially impacting consumer perception of Tylenol and Kenvue's market position.